Rigel (RIGL) Q2 2026 earnings review
Record Product Sales and a Transformative $70M Acquisition
Rigel delivered a solid quarter, highlighted by a record $67.0M in net product sales—up 14% YoY. But the real story is the strategic leap: a $70M upfront payment to in-license VEPPANU, the first FDA-approved PROTAC breast cancer drug. This immediately diversifies Rigel's commercial portfolio. Full-year revenue guidance was raised to $285-$295M. While GAVRETO sales contracted 10% YoY, TAVALISSE and REZLIDHIA drove the top line. The cash balance took a predictable hit from the VEPPANU deal, dropping to $95.3M, but the company remains firmly on track for full-year profitability.
🐂 Bull Case
The $70M licensing deal for VEPPANU immediately adds a high-potential, FDA-approved commercial oncology asset to the bag, perfectly aligning with management's stated M&A strategy without diluting shareholders.
TAVALISSE rebounded aggressively from Q1 seasonality, posting $47.4M (+18% YoY). REZLIDHIA grew 27% YoY to $8.9M, proving the commercial team can drive community adoption.
🐻 Bear Case
Total costs jumped 35% YoY to $55.1M. R&D doubled to $13.9M, and SG&A climbed to $32.6M. Integrating and launching VEPPANU will likely keep expenses elevated, pressuring near-term operating margins.
GAVRETO sales dropped 10% YoY to $10.7M. It is no longer a growth vector and is actively dragging down the overall product portfolio growth rate.
⚖️ Verdict: 🟢
Bullish. Management executed exactly what they promised: leveraging internally generated cash to acquire a late-stage, de-risked asset (VEPPANU) while sustaining double-digit growth in the core commercial portfolio.
Key Themes
VEPPANU Acquisition Transforms Oncology Portfolio
Rigel acquired exclusive global rights to VEPPANU (vepdegestrant) from Arvinas and Pfizer. As the first and only FDA-approved PROTAC for ER+/HER2- breast cancer, it introduces a novel technology to Rigel's sales force. With commercial availability expected in mid-August 2026, this is a massive Accelerating driver that drastically reduces the company's reliance on TAVALISSE.
TAVALISSE and REZLIDHIA Sustain Growth Engine
The legacy portfolio remains highly productive. TAVALISSE grew 18% YoY to $47.4M, shaking off the seasonal reimbursement headwinds seen in Q1. REZLIDHIA grew 27% YoY to $8.9M. This consistent double-digit growth funds the R&D pipeline and the VEPPANU launch.
R289 Clinical Progress on Track
Rigel's primary internal asset, the dual IRAK1/4 inhibitor R289 for lower-risk MDS, is progressing as planned. The Phase 1b dose expansion phase is on track to complete enrollment in H2 2026, with a recommended Phase 2 dose and preliminary data expected by year-end. This sets up a crucial binary catalyst for 2026.
Operating Expense Ramp Reversing Margin Gains
Total costs and expenses ballooned to $55.1M compared to $40.6M a year ago. R&D expenses doubled YoY ($13.9M vs $6.8M), driven by R289 and VEPPANU development costs. SG&A also increased by over $3M. If VEPPANU's launch is slow, these elevated costs will severely compress operating margins.
GAVRETO Contradicts the 'Strong Quarter' Narrative
Despite management celebrating a strong commercial quarter, GAVRETO is visibly lagging. Sales fell 10% YoY to $10.7M. While management previously framed it as a 'stable $10M/quarter' cash cow, the YoY contraction is a structural drag on the portfolio. It is actively cannibalizing total growth percentages.
Cash Position Takes a Major Hit
The cash balance dropped from $155M at the end of 2025 down to $95.3M, entirely due to the $70M upfront payment for VEPPANU. While this was a planned strategic use of capital, it removes the safety net. Rigel is now highly dependent on VEPPANU's immediate commercial success to rebuild its war chest for any future M&A.
Other KPIs
A highly profitable revenue stream driven primarily by a $4.0M regulatory milestone from Kissei for the submission of olutasidenib in Japan, alongside $5.0M from Grifols in royalties and drug supplies. This high-margin revenue continues to provide crucial padding to the bottom line.
While net income looks drastically lower than the $59.6M reported in 25Q2, that prior quarter included a massive $40.0M non-cash revenue release from Eli Lilly. Adjusting for that anomaly, core operational profitability remains Stable, proving the business can self-fund its operations.
Guidance
Accelerating. Management raised the full-year target from the previous $275-$290M range. Importantly, this excludes VEPPANU, meaning the base business is outperforming initial internal expectations.
Stable to Accelerating. Maintained at the high end of prior expectations, driven entirely by TAVALISSE, REZLIDHIA, and GAVRETO. Note: VEPPANU sales are excluded from this figure, providing a potential upside surprise in H2.
Accelerating. Raised from the prior guide of $20-$25M, reflecting better-than-expected milestone achievements and royalty streams from international partners like Kissei and Grifols.
Key Questions
VEPPANU Sales Force Integration
With the mid-August launch of VEPPANU quickly approaching, will you need to significantly expand your commercial sales team to target breast cancer specialists, or can your existing infrastructure absorb the new product?
GAVRETO Floor
GAVRETO sales declined 10% YoY this quarter. At what point do you consider divesting the asset if it continues to contract and command operational focus away from high-growth drivers like TAVALISSE and VEPPANU?
R289 Capital Requirements
With the cash balance down to $95M following the VEPPANU deal, how much capital is modeled for the R289 registrational study in 2027, and will you need to raise external capital to fund it?